IMP: Board resolution on business performance in 2017
IMP: Board resolution on business performance in 2017
Imexpharm Corporation announces the Board resolution dated January 31, 2018 as follows:
1) The Board of Directors approved the report on business performance in 2017:
- Total revenue in 2017: VND1,185.4 billion, increasing 16.1% compared to 2016, achieving 94.1% revenue;
- Profit before tax and before distributing to Science and Technology Fund in 2017: VND162.6 billion, increasing 15.7% compared to 2016, achieving 101.6% revenue.
2) The Board of Directors approved business targets for 2018:
- Total revenue in 2018: VND1,440 billion, increasing 21.5%;
- Profit before tax and before distributing to Science and Technology Fund in 2018: VND190 billion, increasing 16.8%.
3) The Board of Directors authorized the CEO to receive the credit limit in 2018 in commercial banks.
4) The Board of Directors approved the wage unit in 2018, the reward regulation.
HOSE
